Comparable stake leader
Et al Phillip Frost MD
SEC ownership of Cocrystal Pharma, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001412486.
Disclosed value leader
Et al Phillip Frost MD
Comparable rows
26/34
Latest evidence
03 Jun 2026
- Public ticker
- COCP on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Et al Phillip Frost MD
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
26 of 34
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Et al Phillip Frost MD
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
03 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001412486
- Issuer location
- Bothell, WA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Cocrystal Pharma, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Et al Phillip Frost MD
Disclosed value leader
Et al Phillip Frost MD
Comparable rows
26/34
Latest evidence
03 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 18%
8 rows are not safely comparable across share classes.
13D/G row: Et al Phillip Frost MD
Showing 1-8 of 34 holder rows.
Quick read
Et al Phillip Frost MD leads the comparable SEC ownership view at 18%.
26 of 34 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Et al Phillip Frost MD's linked filing trail.
Comparable ownership
Top 5
Et al Phillip Frost MD
18%
VANGUARD CAPITAL MANAGEMENT LLC
1.7%
RENAISSANCE TECHNOLOGIES LLC
0.9%
GEODE CAPITAL MANAGEMENT, LLC
0.65%
BlackRock, Inc.
0.53%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 34 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Et al Phillip Frost MD |
13D/G
3/4/5
Phillip Frost, M.D. · Director, 10%+ Owner
|
18%
|
$3,078,992
2,462,012 shares
|
+$1,349,571 | 28 Oct 2025 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
1.7%
|
$242,371
239,971 shares
|
— | 31 Mar 2026 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
0.9%
|
$125,167
123,928 shares
|
— | 31 Mar 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.65%
|
$91,147
90,231 shares
|
— | 31 Mar 2026 |
| BlackRock, Inc. |
13F
Company
|
0.53%
|
$74,483
73,746 shares
|
— | 31 Mar 2026 |
| T3 Companies, LLC |
13F
Company
|
0.37%
|
$52,015
51,500 shares
|
— | 31 Mar 2026 |
| XTX Topco Ltd |
13F
Company
|
0.26%
|
$36,391
36,031 shares
|
— | 31 Mar 2026 |
| Neuberger Berman Group LLC |
13F
Company
|
0.23%
|
$32,205
31,886 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$219,806.
Buys
$219,806
Insiders: 1
Sells
$0
Insiders: 0
Net
+$219,806
Shares: +229,000
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 229,000
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 205,000 | 0 | $197,018 | $0 | +$197,018 |
| 6-9 | 24,000 | 0 | $22,787 | $0 | +$22,787 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-9 of 9 reporting-owner rows connected to Cocrystal Pharma, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
9
Largest Forms 3/4/5 holder
Et al Phillip Frost MD
Net 12M change
+$219,806
Latest report
03 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Et al Phillip Frost MD | Director, 10%+ Owner | $2,930,502 | +$219,806 | +8.1% | Mixed | 24 Feb 2026 |
| Fred Hassan | Director | $2,922,384 | Mixed | 09 Jan 2026 | ||
| Richard C. Pfenniger Jr. | Director | $94,867 | Mixed | 09 Jan 2026 | ||
| James Joseph Martin | Co-CEO and CFO | $71,394 | Mixed | 09 Jan 2026 | ||
| Sam Lee | President and Co-CEO | Mixed | 09 Jan 2026 | |||
| James Sapirstein | Chief Executive Officer | Mixed | 03 Jun 2026 | |||
| Anthony J. Japour | Director | Mixed | 09 Jan 2026 | |||
| Roger D. Kornberg | Director | Mixed | 09 Jan 2026 | |||
| Steven D. Rubin | Director | Mixed | 09 Jan 2026 |
Recent insider transactions for Cocrystal Pharma, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| James Sapirstein | COCP | Stock Options (Right to Buy) | Award | 235,000 | 235,000 | 03 Jun 2026 | Direct | |||
| Et al Phillip Frost MD | COCP | Common Stock | Purchase | 1.06% | $19,952 | $0.9976 | 20,000 | 1,908,551 | 24 Feb 2026 | By Frost Gamma Investments Trust |
| Et al Phillip Frost MD | COCP | Common Stock | Purchase | 2.72% | $47,280 | $0.9456 | 50,000 | 1,888,551 | 06 Feb 2026 | By Frost Gamma Investments Trust |
| Roger D. Kornberg | COCP | Stock Options (Right to Buy) | Award | 24,615 | 24,615 | 09 Jan 2026 | Direct | |||
| Richard C. Pfenniger Jr. | COCP | Stock Options (Right to Buy) | Award | 16,410 | 16,410 | 09 Jan 2026 | Direct | |||
| Sam Lee | COCP | Stock Options (Right to Buy) | Award | 49,229 | 49,229 | 09 Jan 2026 | Direct | |||
| Fred Hassan | COCP | Stock Options (Right to Buy) | Award | 16,410 | 16,410 | 09 Jan 2026 | Direct | |||
| James Joseph Martin | COCP | Stock Options (Right to Buy) | Award | 49,229 | 49,229 | 09 Jan 2026 | Direct | |||
| Et al Phillip Frost MD | COCP | Stock Options (Right to Buy) | Award | 24,615 | 24,615 | 09 Jan 2026 | Direct | |||
| Anthony J. Japour | COCP | Stock Options (Right to Buy) | Award | 16,410 | 16,410 | 09 Jan 2026 | Direct | |||
| Steven D. Rubin | COCP | Stock Options (Right to Buy) | Award | 16,410 | 16,410 | 09 Jan 2026 | Direct | |||
| Et al Phillip Frost MD | COCP | Common Stock | Purchase | 2.8% | $47,275 | $0.9455 | 50,000 | 1,838,551 | 31 Dec 2025 | By Frost Gamma Investments Trust |
| Et al Phillip Frost MD | COCP | Common Stock | Purchase | 1.13% | $19,310 | $0.9655 | 20,000 | 1,788,551 | 30 Dec 2025 | By Frost Gamma Investments Trust |
| Et al Phillip Frost MD | COCP | Common Stock | Purchase | 2.31% | $38,944 | $0.9736 | 40,000 | 1,768,551 | 26 Dec 2025 | By Frost Gamma Investments Trust |
| Et al Phillip Frost MD | COCP | Common Stock | Purchase | 1.47% | $24,258 | $0.9703 | 25,000 | 1,728,551 | 24 Dec 2025 | By Frost Gamma Investments Trust |
| Et al Phillip Frost MD | COCP | Common Stock | Purchase | 0.24% | $3,975 | $0.9938 | 4,000 | 1,703,551 | 26 Nov 2025 | By Frost Gamma Investments Trust |
| Et al Phillip Frost MD | COCP | Common Stock | Purchase | 1.19% | $18,812 | $0.9406 | 20,000 | 1,699,551 | 25 Nov 2025 | By Frost Gamma Investments Trust |
| Et al Phillip Frost MD | COCP | Common Stock | Award | 27.2% | 359,713 | 1,679,551 | 28 Oct 2025 | By Frost Gamma Investments Trust | ||
| Et al Phillip Frost MD | COCP | Warrants | Award | 719,426 | 719,426 | 28 Oct 2025 | By Frost Gamma Investments Trust | |||
| Fred Hassan | COCP | Common Stock | Award | 35.2% | 359,713 | 1,383,009 | 28 Oct 2025 | Direct | ||
| Fred Hassan | COCP | Warrants | Award | 719,426 | 719,426 | 28 Oct 2025 | Direct | |||
| Richard C. Pfenniger Jr. | COCP | Common Stock | Award | 175.4% | 20,000 | 31,400 | 28 Oct 2025 | Direct | ||
| Richard C. Pfenniger Jr. | COCP | Warrants | Award | 40,000 | 40,000 | 28 Oct 2025 | Direct | |||
| James Joseph Martin | COCP | Common Stock | Award | 8.87% | 3,598 | 44,167 | 28 Oct 2025 | Direct | ||
| James Joseph Martin | COCP | Warrants | Award | 7,196 | 7,196 | 28 Oct 2025 | Direct |
* marks a reported price that did not pass the local price check.